Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19835522 | 1.00 | HTR2C (0.41) | HTR2CHTR2AKDM1AKDM1BSLC6A2 | |
| SCHEMBL19829916 | 1.00 | HTR2C (0.41) | HTR2CHTR2AKDM1AKDM1BSLC6A2 | |
| SCHEMBL19829920 | 1.00 | HTR2C (0.41) | HTR2CHTR2AKDM1AKDM1BSLC6A2 | |
| SCHEMBL19828018 | 1.00 | HTR2C (0.41) | HTR2CHTR2AKDM1AKDM1BSLC6A2 | |
| SCHEMBL19828131 | 1.00 | HTR2C (0.41) | HTR2CHTR2AKDM1AKDM1BSLC6A2 | |
| SCHEMBL19830099 | 1.00 | HTR2C (0.41) | HTR2CHTR2AKDM1AKDM1BSLC6A2 | |
| SCHEMBL19828022 | 1.00 | HTR2C (0.41) | HTR2CHTR2AKDM1AKDM1BSLC6A2 | |
| SCHEMBL19830046 | 0.87 | KDM1A (0.35) | HTR2CHTR2AKDM1AKDM1BSLC6A2 | |
| SCHEMBL19827864 | 0.87 | KDM1A (0.35) | HTR2CHTR2AKDM1AKDM1BSLC6A2 | |
| SCHEMBL19830045 | 0.87 | KDM1A (0.35) | HTR2CHTR2AKDM1AKDM1BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077090-B2 | Compounds and compositions and uses thereof | SUNOVION PHARMACEUTICALS INC. (MA) | 2021-08-03 | — | — | US | disclosed |
| US-20180028492-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | PGI DRUG DISCOVERY LLC | 2018-02-01 | — | — | US | disclosed |
| US-20180028492-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | PGI DRUG DISCOVERY LLC | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077090-B2 | Compounds and compositions and uses thereof | ACHE, CHAT, MAOB | HTR2C 196/4885HTR2A 199/4885KDM1A 4074/4885 |
| US-20180028492-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ACHE, CHAT, MAOB | HTR2C 196/4885HTR2A 199/4885KDM1A 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.